Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-64680
Weller, M; Stupp, R; Wick, W (2012). Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncology, 13(9):e375-e382.
View at publisher
The lifetime risk of having epileptic seizures is profoundly increased in patients with cancer: about 20% of all patients with systemic cancer may develop brain metastases. These patients and those with primary brain tumours have a lifetime risk of epilepsy of 20-80%. Moreover, exposure to chemotherapy or radiotherapy to the brain, cancer-related metabolic disturbances, stroke, and infection can provoke seizures. The management of epilepsy in patients with cancer includes diagnosis and treatment of the underlying cerebral pathological changes, secondary prophylaxis with antiepileptic drugs, and limiting of the effect of epilepsy and its treatment on the efficacy and tolerability of anticancer treatments, cognitive function, and quality of life. Because of the concern of drug-drug interactions, the pharmacological approach to epilepsy requires a multidisciplinary approach, specifically in a setting of rapidly increasing choices of agents both to treat cancer and cancer-associated epilepsy.
66 downloads since deposited on 08 Oct 2012
30 downloads since 12 months
|Item Type:||Journal Article, refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology|
|DDC:||610 Medicine & health|
|Deposited On:||08 Oct 2012 12:58|
|Last Modified:||07 Dec 2012 09:37|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page